ADA: Sanofi's Toujeo tops Novo Nordisk's Tresiba in tough-to-treat diabetes subgroup
admin 10th June 2019 Uncategorised 0Sanofi’s Toujeo has been battling it out against Novo Nordisk’s Tresiba in the next-generation basal insulin market, but new data could give it an edge in one key pool of diabetes patients.
More: ADA: Sanofi's Toujeo tops Novo Nordisk's Tresiba in tough-to-treat diabetes subgroup
Source: fierce